This session will present updated findings from the groundbreaking research study analyzing clinical practice gaps in the implementation of personalized medicine for advanced non–small cell lung cancer (aNSCLC). Building on a previously published seven-step clinical practice gap framework, which identified key barriers to optimal use of biomarker-directed therapies, this new analysis uses more recent data […]
Engaging with the global community is now more vital than ever for advancing personalized medicine, especially when considering shared knowledge, coordinated policy development, and international clinical adoption strategies. With rapid innovations in advanced technologies—including cell-based and gene therapies—new models of care are emerging, such as regional clinical delivery hubs in Europe designed to streamline patient […]
MODERATOR | Clifton Leaf, Visiting Member, Ellison Medical Institute; former Editor-in-Chief, FORTUNE Magazine KEYNOTE SPEAKER | Helmy Eltoukhy, Ph.D., Co-Chief Executive Officer & Chairman of the Board, Guardant Health KEYNOTE SPEAKER | AmirAli Talasaz, Ph.D., Co-Chief Executive Officer & Director, Guardant Health
MODERATOR | Dan Roden, M.D., Professor of Medicine, Pharmacology, & Biomedical Informatics; Senior Vice President, Personalized Medicine, Vanderbilt University Medical Center PANELIST | Doug Biehn, President & Chief Executive Officer, Octave Bioscience, Inc. PANELIST | Edward Hickey, President & Chair, American Association of Kidney Patients (AAKP) Veterans Health Initiative, U.S.M.C. PANELIST | Damon Hostin, Global Lead, […]
PRESENTER | Mara Aspinall, Partner, Illumina Ventures AWARDEE | George Poste, D.V.M., Ph.D., Regents’ Professor and Del E. Webb Chair in Health Innovation; Chief Scientist, Complex Adaptive Systems Initiative, Arizona State University
Machine learning and artificial intelligence technologies can drive biomarker discovery and validation and more readily explore divergent effects of preventive and treatment interventions across extensive data sets. What might this mean for the future of personalized medicine and what is being done to realize that future? MODERATOR | Douglas Clark, M.D., Chief Pathologist, Life Sciences & […]
Sponsored by:
MODERATOR | Clifton Leaf, Visiting Member, Ellison Medical Institute; former Editor-in-Chief, FORTUNE Magazine KEYNOTE SPEAKER | Anthony Sireci, M.D., Senior Vice President, Clinical Biomarkers, Laboratories & Diagnostics, Eli Lilly
By detecting molecular cancer signals in blood samples of seemingly healthy patients, a new generation of early cancer detection tests promises to put more patients on the path to personalized cancer treatment, sooner, when cancer may be more effectively treated. What might this mean for the future of cancer care? Leading voices discuss. MODERATOR | Omar […]
